Abstract
Abnormal uterine bleeding (AUB) is the primary reason for one-third of all gynecology visits and more than half of all hysterectomies. After excluding pregnancy, the basic evaluation consists of a thorough history and physical examination, anatomic assessment by ultrasound, laboratory evaluation, and, often, endometrial biopsy. Irregular cycles are commonly due to anovulation resulting from polycystic ovary syndrome, but other causes and coexisting conditions must be excluded. Medical management will significantly improve or resolve symptoms in many women and can include hormonal therapy, nonsteroidal antiinflammatory drugs, or tranexamic acid. When AUB does not respond to standard hormonal therapies, antibiotic treatment of subclinical endometritis can be considered. Surgical approaches remain important options for both evaluation and treatment of AUB.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Coulter A, Bradlow J, Agass M, Martin-Bates C, Tulloch A. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol. 1991;98:789–96.
Carlson KJ, Nichols DH, Schiff I. Indications for hysterectomy. N Engl J Med. 1993;328:856–60.
Munro MG, Critchley HO, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3–13.
Fraser IS. Menorrhagia–a pragmatic approach to the understanding of causes and the need for investigations. Br J Obstet Gynaecol. 1994;101 Suppl 11Suppl 11:3–7.
Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA. 1993;269(14):1823–8.
Fraser IS, Critchley HO, Munro MG, Broder M, Writing Group for this Menstrual Agreement Process. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007; 87(3):466–76.
Falco P, Zagonari S, Gabrielli S, Bevini M, Pilu G, Bovicelli L. Sonography of pregnancies with first-trimester bleeding and a small intrauterine gestational sac without a demonstrable embryo. Ultrasound Obstet Gynecol. 2003;21(1):62–5.
Barnhart K, Esposito M, Coutifaris C. An update on the medical treatment of ectopic pregnancy. Obstet Gynecol Clin North Am. 2000;27:653–67.
Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol. 1995;86(5):775–9.
Eschenbach DA. Acute pelvic inflammatory disease: etiology, risk factors and pathogenesis. Clin Obstet Gynecol. 1976;19(1): 147–69.
Heatley MK. The association between clinical and pathological features in histologically identified chronic endometritis. J Obstet Gynaecol. 2004;24(7):801–3.
Eckert LO, Thwin SS, Hillier SL, Kiviat NB, Eschenbach DA. The antimicrobial treatment of subacute endometritis: a proof of concept study. Am J Obstet Gynecol. 2004;190(2):305–13.
Gotz HM, van Bergen JE, Veldhuijzen IK, Broer J, Hoebe CJ, Richardus JH. A prediction rule for selective screening of Chlamydia trachomatis infection. Sex Transm Infect. 2005;81(1):24–30.
Marrazzo JM, Handsfield HH, Whittington WL. Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstet Gynecol. 2002;100(3):579–84.
Jones H. Clinical pathway for evaluating women with abnormal uterine bleeding. Obstet Gynecol Surv. 2002;57:22–4.
Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188: 100–7.
Bazot M, Cortez A, Darai E, Rouger J, Chopier J, Antoine JM, et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod. 2001;16:2427–33.
Nathani F, Clark TJ. Uterine polypectomy in the management of abnormal uterine bleeding: a systematic review. J Minim Invasive Gynecol. 2006;13(4):260–8.
Clevenger-Hoeft M, Syrop CH, Stovall DW, Van Voorhis BJ. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol. 1999;94:516.
Armstrong AJ, Hurd WW, Shaker ME, Elguero SB, Barker NG, Zanotti KM. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol. 2012;19(5):562–71.
Sorosky J. Endometrial cancer. Obstet Gynecol. 2008;112(1): 186–7.
Young RH, Clement PB. Pseudoneoplastic glandular lesions of the uterine cervix. Semin Diagn Pathol. 1991;8(4):234–49.
Rosenthal AN, Panoskaltsis T, Smith T, Soutter WP. The frequency of significant pathology in women attending a general gynaecological service for postcoital bleeding. BJOG. 2001;108(1):103–6.
Krettek JE, Arkin SI, Chaisilwattana P, Monif GR. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol. 1993;81(5):728–31.
Zhang J, Salamonsen LA. In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab. 2002;87(5): 2346–51.
Brenner PF. Differential diagnosis of abnormal uterine bleeding. Am J Obstet Gynecol. 1996;175(3 Pt 2):766–9.
Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(1): 1–17.
Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. p. 377–84.
Hurd WW, Abdel-Rahman MY, Ismail SA, Abdellah MA, Schmotzer CL, Sood A. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril. 2011;96:1043–7.
Pugeat M, Ducluzeau PH. Insulin resistance, polycystic ovary syndrome and metformin. Drugs. 1999;58 Suppl 1Suppl 1:41–6.
Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol. 2004;191(3):713–7.
Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis. 2004;11(4): 337–41.
Falcone T, Desjardins C, Bourque J, Granger L, Hemmings R, Quiros E. Dysfunctional uterine bleeding in adolescents. J Reprod Med. 1994;39:761–4.
Committee ACOG. Opinion no. 451: Von Willebrand disease in women. Obstet Gynecol. 2009;114:1439–43.
Minakuchi K, Hirai K, Kawamura N, Ishiko O, Kanaoka Y, Ogita S. Case of hemorrhagic shock due to hypermenorrhea during anticoagulant therapy. Arch Gynecol Obstet. 2000;264(2):99–100.
Woo YL, White B, Corbally R, Byrne M, O’Connell N, O’Shea E, et al. Von Willebrand’s disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis. 2002;13(2):89–93.
Kouides PA. Menorrhagia from a haematologist’s point of view. Part I: initial evaluation. Haemophilia. 2002;8(3):330–8.
Sahin Y, Kelestimur F. The frequency of late-onset 21-hydroxylase and 11 beta-hydroxylase deficiency in women with polycystic ovary syndrome. Eur J Endocrinol. 1997;137(6):670–4.
Kouides PA. Evaluation of abnormal bleeding in women. Curr Hematol Rep. 2002;1(1):11–8.
Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012;120(1):197–206.
DeVore GR, Owens O, Kase N. Use of intravenous premarin in the treatment of dysfunctional uterine bleeding—a double-blind randomized control study. Obstet Gynecol. 1982;59:285.
Hestinger M, Stockenhuber F, Schneider B, Pabinger I, Brenner B, Wagner B, et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int. 1990;38:1181.
Zreik TG, Odunsi K, Cass I, Olive DL, Sarrel P. A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy. Fertil Steril. 1999;71(2):373–5.
Tepper N, Curtis KM, Jamieson DJ, Marchbanks PA, Centers for Disease Control and Prevention (CDC). Update to CDC’s U.S. medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. Morb Mortal Wkly Rep. 2011;60:878–83.
Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas. 2003;45(1):1–14.
Larsson PG, Bergman B, Forsum U, Pahlson C. Treatment of bacterial vaginosis in women with vaginal bleeding complications or discharge and harboring Mobiluncus. Gynecol Obstet Invest. 1990;29(4):296–300.
Moller BR, Kristiansen FV, Thorsen P, Mogensen SC. Sterility of the uterine cavity. Acta Obstet Gynecol Scand. 1995;74:216–9.
Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6): 551–66.
Sulak PJ. The career woman and oral contraceptive use. Int J Fertil. 1991;36(Suppl2):90–7.
Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol. 1997;89(2):179–83.
Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68:89–96.
Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev. 2008;(1):CD001016.
Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelä A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia; randomized trial 5 year follow up. JAMA. 2004;291:1456–63.
Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65(2):129–32.
Nilsson CG, Lahteenmaki PL, Luukkainen T, Robertson DN. Sustained intrauterine release of levonorgestrel over five years. Fertil Steril. 1986;45(6):805–7.
Cooke I, Lethaby A, Farquhar C. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(2):CD000249.
Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf. 2008;31(4):275–82.
Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;(4):CD000400.
ACOG Committee on Practice Bulletins—Gynecology. ACOG practice bulletin no. 81: endometrial ablation. Obstet Gynecol. 2007;109:1233–48.
Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(2):CD000329.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Elguero, S., Lappen, J.R., Hurd, W.W. (2013). Abnormal Uterine Bleeding. In: Falcone, T., Hurd, W. (eds) Clinical Reproductive Medicine and Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6837-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6837-0_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6836-3
Online ISBN: 978-1-4614-6837-0
eBook Packages: MedicineMedicine (R0)